Unsaturated Phospholipids Restore Membrane Plasticity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dyslipidemia and metabolic syndrome primarily focus on insulin secretion and blood sugar levels, failing to restore cellular functionality and often lead to ineffectiveness and resistance due to global disruption of membrane mechanisms, particularly in non-adipocyte cells unable to synthesize neutral lipids.
Innovation Solution
Development of novel compounds with a polar head and a single unsaturated fatty acid, such as mannide monooleate, that do not induce cellular toxicity, restore membrane plasticity, and can treat established dyslipidemia by acting on membrane functionality without producing diunsaturated phospholipids or causing intracellular calcium mobilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments focusing on insulin secretion and blood sugar levels are used, then blood sugar control is improved, but cellular functionality is not restored and resistance develops due to membrane mechanism disruption
Solution Approach 1:
The patent introduces phospholipids with unsaturated fatty acids as intermediary substances that restore membrane fluidity and functionality. These phospholipids act as mediators between the harmful saturated fatty acids and the cell membrane, preventing the disruption of membrane mechanisms while allowing conventional diabetes treatments to remain effective. The unsaturated phospholipids insert themselves into the membrane structure, maintaining proper membrane fluidity and preventing the accumulation of harmful saturated fats from causing resistance.
2Stability of the object's composition
If unsaturated fatty acids are used to counter saturated fatty acid toxicity, then membrane plasticity is restored, but cellular toxicity occurs in non-adipocyte cells unable to synthesize neutral lipids
Solution Approach 1:
The patent applies local quality by providing unsaturated phospholipids specifically to non-adipocyte cells that cannot synthesize their own neutral lipids. Instead of systemically administering unsaturated fatty acids that would be toxic to all cells, the invention delivers phospholipids directly to the affected cells through the bloodstream. This localized approach ensures that only the cells needing membrane restoration receive the unsaturated fatty acids, avoiding the toxic accumulation that would occur in adipocytes and other cells capable of synthesizing neutral lipids.
Solution Approach 2:
The patent changes the chemical parameters of the administered substance by using phospholipids with specific unsaturated fatty acid chains (such as oleic, linoleic, or alpha-linolenic acids) rather than free unsaturated fatty acids. This parameter change - converting from free fatty acids to esterified phospholipid forms - fundamentally alters the biochemical behavior, allowing the substance to restore membrane plasticity without triggering the toxic pathway that leads to intracellular membrane proliferation and cell death in non-adipocyte cells.
3Quantity of substance
If saturated fatty acids accumulate in biological membranes, then energy storage is increased, but membrane plasticity is disrupted and cellular dysfunction occurs
Solution Approach 1:
The patent converts the harmful effect of saturated fatty acid accumulation into a beneficial outcome by administering unsaturated phospholipids that compete with saturated fats for incorporation into membrane structures. The unsaturated phospholipids displace the harmful saturated fatty acids from membrane positions, restoring membrane plasticity while allowing the saturated fats to be redirected to energy storage depots. This transforms the原本的有害积累 into a beneficial energy reserve, separating the energy storage function from the membrane structural function.
Data Source
AI summary
The present invention relates to the field of medicine. It more particularly relates to the use of compounds for preventing and/or treating dyslipidemia in a subject, said dyslipidemia typically being linked to the excess presence in the biological membranes, including in the biological membranes of non-adipocyte cells, of fatty acids, in particular of saturated long-chain fatty acids, and/or of sterols. The invention also relates to compositions, in particular pharmaceutical compositions and food supplements or complements, comprising such compounds, and to the uses thereof for preventing and/or treating dyslipidemia. The compounds and compositions according to the invention can in particular be advantageously used for preventing and/or treating a pathological condition selected from metabolic syndrome and/or a symptom or abnormality characteristic of metabolic syndrome, preferably for preventing or treating type 2 diabetes mellitus or hepatic steatosis.